# Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

> **NCT01798108** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 31 (actual)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **RADIATION:** Radium-223 dichloride (BAY88-8223)

## Key facts

- **NCT ID:** NCT01798108
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08-14
- **Primary completion:** 2003-06-25
- **Final completion:** 2003-06-25
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01798108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01798108, "Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01798108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*